About this trial
Preeclampsia and intrauterine growth retardation (IUGR) are serious and frequent pathologies, specific to pregnancy. They represent 70 000 new cases a year, or 9% of pregnancies and cause 50,000 premature births per year in France. The consequences in terms of morbidity and perinatal morbidity and the medical and economic costs make it an issue public health. Pre-eclampsia associates maternal hypertension with dysfunction kidney. There is no cure for pre-eclampsia or IUGR vascular during pregnancy. These pathologies invariably evolve towards a maternal and / or fetal aggravation sometimes very fast. Primary prevention and secondary education and screening for these pathologies are still insufficient. A better understanding of the pathophysiology of these placental vascular pathologies is necessary for the development of supported medical, obstetric and pediatric that will improve the state of health maternal and neonatal
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
pregnant women
With or without vascular pathology
Disqualifiers
refusal to participate
multiple pregnancy
major fetal malformation diagnosed during pregnancy follow-up
Trial population
pregnant women with or without vascular pathology
Trial design
Cohort
Prospective
Treatments tested in this trial
collect of placenta, blood and urinary samples at delivery
Other interventioncollect of placenta, blood and urinary samples at delivery
Treatment groups
Trial outcomes
Primary outcomes
genomic analysis on placenta
by chromatin immunoprecipitation-sequencing (ChIP-seq)
Secondary outcomes
genomic analysis on blood
by ChIP-seq
genomic analysis on placenta
by immunohistochemistry an polymerase chain-reaction
VEGF blood level
PLGF blood level
Sponsors and contacts
Click on the lead sponsor to view all of their trials.